FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:154-164 January 13, 2005 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied.

Methods We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received a diagnosis of prostate cancer in the period from 1992 through 1997. The primary outcomes were the occurrence of any fracture and the occurrence of a fracture resulting in hospitalization. Cox proportional-hazards analyses were adjusted for characteristics of the patients and the cancer, other cancer treatment received, and the occurrence of a fracture or the diagnosis of osteoporosis during the 12 months preceding the diagnosis of cancer.

Results Of men surviving at least five years after diagnosis, 19.4 percent of those who received androgen-deprivation therapy had a fracture, as compared with 12.6 percent of those not receiving androgen-deprivation therapy (P<0.001). In the Cox proportional-hazards analyses, adjusted for characteristics of the patient and the tumor, there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fracture.

Conclusions Androgen-deprivation therapy for prostate cancer increases the risk of fracture.

Source Information

From the Departments of Internal Medicine (V.B.S., Y.-F.K., J.L.F., J.S.G.) and Preventive Medicine and Community Health (Y.-F.K., J.L.F., J.S.G.), and the Sealy Center on Aging (V.B.S., Y.-F.K., J.L.F., J.S.G.) — all at the University of Texas Medical Branch, Galveston.

Address reprint requests to Dr. Shahinian at the Department of Internal Medicine, University of Texas Medical Branch, John Sealy Annex, Rm. 4.200, 301 University Blvd., Galveston, TX 77555-0562, or at vbshahin{at}utmb.edu.

Full Text of this Article

This article has been cited by other articles:

• Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C.M., Oddens, J., Poortmans, P. M.P., Gez, E., Kil, P., Akdas, A., Soete, G., Kariakine, O., van der Steen-Banasik, E. M., Musat, E., Pierart, M., Mauer, M. E., Collette, L., the EORTC Radiation Oncology Group and Genito-Urin, (2009). Duration of Androgen Suppression in the Treatment of Prostate Cancer. NEJM 360: 2516-2527 [Abstract] [Full Text]  
• Giltay, E. J., Gooren, L. J. G. (2009). Potential Side Effects of Androgen Deprivation Treatment in Sex Offenders. J Am Acad Psychiatry Law 37: 53-58 [Abstract] [Full Text]  
• Van den Wyngaert, T., Huizing, M. T., Fossion, E., Vermorken, J. B. (2009). Bisphosphonates in Oncology: Rising Stars or Fallen Heroes. The Oncologist 14: 181-191 [Abstract] [Full Text]  
• Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., Smith, M. R. (2009). Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31. JCO 27: 92-99 [Abstract] [Full Text]  
• Saylor, P. J., Smith, M. R. (2009). Prostate Cancer Survivorship: Metabolic Complications of Androgen Deprivation Therapy. Am Soc Clin Oncol Ed Book 2009: 263-268 [Abstract] [Full Text]  
• Lustberg, M., Shapiro, C. L. (2009). Physical Challenges of Adult Cancer Survivors. Am Soc Clin Oncol Ed Book 2009: 564-569 [Abstract] [Full Text]  
• Wang, W., Yuasa, T., Tsuchiya, N., Maita, S., Kumazawa, T., Inoue, T., Saito, M., Ma, Z., Obara, T., Tsuruta, H., Satoh, S., Habuchi, T. (2008). Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 15: 943-952 [Abstract] [Full Text]  
• Saad, F., Adachi, J. D., Brown, J. P., Canning, L. A., Gelmon, K. A., Josse, R. G., Pritchard, K. I. (2008). Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer. JCO 26: 5465-5476 [Abstract] [Full Text]  
• Szulc, P. (2008). Pathophysiology and Diagnosis of Osteoporosis in Aging Men. IBMS BoneKEy 5: 370-380 [Abstract] [Full Text]  
• Smith, M. R. (2008). Osteoporosis in Men With Prostate Cancer: Now for the Fracture Data. JCO 26: 4371-4372 [Full Text]  
• Greenspan, S. L., Nelson, J. B., Trump, D. L., Wagner, J. M., Miller, M. E., Perera, S., Resnick, N. M. (2008). Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy. JCO 26: 4426-4434 [Abstract] [Full Text]  
• Lu-Yao, G. L., Albertsen, P. C., Moore, D. F., Shih, W., Lin, Y., DiPaola, R. S., Yao, S.-L. (2008). Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer. JAMA 300: 173-181 [Abstract] [Full Text]  
• Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., Smith, M. R. (2008). Management of Complications of Prostate Cancer Treatment. CA Cancer J Clin 58: 196-213 [Abstract] [Full Text]  
• Khosla, S., Amin, S., Orwoll, E. (2008). Osteoporosis in Men. Endocr. Rev. 29: 441-464 [Abstract] [Full Text]  
• Qaseem, A., Snow, V., Shekelle, P., Hopkins, R. Jr., Forciea, M. A., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee, (2008). Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED 148: 680-684 [Abstract] [Full Text]  
• Liu, H., Paige, N. M., Goldzweig, C. L., Wong, E., Zhou, A., Suttorp, M. J., Munjas, B., Orwoll, E., Shekelle, P. (2008). Screening for Osteoporosis in Men: A Systematic Review for an American College of Physicians Guideline. ANN INTERN MED 148: 685-701 [Abstract] [Full Text]  
• Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crino, L., Dirix, L., Gnant, M., Gralow, J., Hadji, P., Hortobagyi, G. N., Jonat, W., Lipton, A., Monnier, A., Paterson, A. H. G., Rizzoli, R., Saad, F., Thurlimann, B. (2008). Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420-432 [Abstract] [Full Text]  
• Roach, M. III, Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., Pilepich, M. V. (2008). Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610. JCO 26: 585-591 [Abstract] [Full Text]  
• Brufsky, A. M. (2008). Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives. The Oncologist 13: 187-195 [Abstract] [Full Text]  
• Greenspan, S. L. (2008). Approach to the Prostate Cancer Patient with Bone Disease. J. Clin. Endocrinol. Metab. 93: 2-7 [Abstract] [Full Text]  
• Shahinian, V. B., Kuo, Y.-f., Freeman, J. L., Orihuela, E., Goodwin, J. S. (2007). Characteristics of Urologists Predict the Use of Androgen Deprivation Therapy for Prostate Cancer. JCO 25: 5359-5365 [Abstract] [Full Text]  
• Brown, J. E., Ellis, S. P., Lester, J. E., Gutcher, S., Khanna, T., Purohit, O.-P., McCloskey, E., Coleman, R. E. (2007). Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. Clin. Cancer Res. 13: 5406-5410 [Abstract] [Full Text]  
• Kaseb, A. O., Chinnakannu, K., Chen, D., Sivanandam, A., Tejwani, S., Menon, M., Dou, Q. P., Reddy, G. P.-V. (2007). Androgen Receptor and E2F-1 Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer. Cancer Res. 67: 7782-7788 [Abstract] [Full Text]  
• Wilkinson, G. S., Kuo, Y.-F., Freeman, J. L., Goodwin, J. S. (2007). Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis. JNCI J Natl Cancer Inst 99: 1016-1024 [Abstract] [Full Text]  
• Montano, M., Flanagan, J. N., Jiang, L., Sebastiani, P., Rarick, M., LeBrasseur, N. K., Morris, C. A., Jasuja, R., Bhasin, S. (2007). Transcriptional Profiling of Testosterone-Regulated Genes in the Skeletal Muscle of Human Immunodeficiency Virus-Infected Men Experiencing Weight Loss. J. Clin. Endocrinol. Metab. 92: 2793-2802 [Abstract] [Full Text]  
• Rajendran, R. R., Kao, G. D. (2007). "No Turning Bax" in the Combined Battle against Prostate Cancer:. Clin. Cancer Res. 13: 3435-3438 [Full Text]  
• Lata, P. F., Elliott, M. E. (2007). Patient Assessment in the Diagnosis, Prevention, and Treatment of Osteoporosis. Nutr Clin Pract 22: 261-275 [Abstract] [Full Text]  
• Wilt, T. J., Ensrud, K. E. (2007). The If's, And's, or But's Regarding Bisphosphonates for Prostate Cancer. JNCI J Natl Cancer Inst 99: 744-745 [Full Text]  
• Michaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., Smith, M. R. (2007). Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men With Prostate Cancer. JCO 25: 1038-1042 [Abstract] [Full Text]  
• Greenspan, S. L., Nelson, J. B., Trump, D. L., Resnick, N. M. (2007). Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial. ANN INTERN MED 146: 416-424 [Abstract] [Full Text]  
• Schroder, F. H (2007). Early versus delayed endocrine therapy for prostate cancer. Endocr Relat Cancer 14: 1-11 [Abstract] [Full Text]  
• Wilcox, A., Carnes, M. L, Moon, T. D, Tobias, R., Baade, H., Stamos, E., Elliott, M. E (2006). Androgen Deprivation in Veterans with Prostate Cancer: Implications for Skeletal Health. The Annals of Pharmacotherapy 40: 2107-2114 [Abstract] [Full Text]  
• Brown, J. E., Ellis, S. P., Silcocks, P., Blumsohn, A., Gutcher, S. A., Radstone, C., Hancock, B. W., Hatton, M. Q., Coleman, R. E. (2006). Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.. Clin. Cancer Res. 12: 6480-6486 [Abstract] [Full Text]  
• Smith, M. R. (2006). Treatment-related osteoporosis in men with prostate cancer.. Clin. Cancer Res. 12: 6315s-6319s [Abstract] [Full Text]  
• Keating, N. L., O'Malley, A. J., Smith, M. R. (2006). Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer. JCO 24: 4448-4456 [Abstract] [Full Text]  
• Hidaka, S., Okamoto, Y., Uchiyama, S., Nakatsuma, A., Hashimoto, K., Ohnishi, S. T., Yamaguchi, M. (2006). Royal Jelly Prevents Osteoporosis in Rats: Beneficial Effects in Ovariectomy Model and in Bone Tissue Culture Model. Evid Based Complement Alternat Med 3: 339-348 [Abstract] [Full Text]  
• Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., Goodwin, J. S. (2006). Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.. JNCI J Natl Cancer Inst 98: 839-845 [Abstract] [Full Text]  
• Michaud, L. B., Goodin, S. (2006). Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 63: 419-430 [Abstract] [Full Text]  
• Vessella, R. L., Guise, T. A., Susman, E. S., Suva, L. J., Clines, G. A., Kominsky, S. L., Weber, K. L., Chirgwin, J. M., McCauley, L. K., Kozlow, W. (2006). Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA. IBMS BoneKEy 3: 15-42 [Full Text]  
• Lee, H., Finkelstein, J. S., Miller, M., Comeaux, S. J., Cohen, R. I., Leder, B. Z. (2006). Effects of Selective Testosterone and Estradiol Withdrawal on Skeletal Sensitivity to Parathyroid Hormone in Men. J. Clin. Endocrinol. Metab. 91: 1069-1075 [Abstract] [Full Text]  
• Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., Goodwin, J. S. (2006). Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.. Arch Intern Med 166: 465-471 [Abstract] [Full Text]  
• Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., Resnick, N. M. (2005). Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer. J. Clin. Endocrinol. Metab. 90: 6410-6417 [Abstract] [Full Text]  
• Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., Pashos, C. L. (2005). Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer. JCO 23: 7897-7903 [Abstract] [Full Text]  
• Hashine, K., Numata, K., Azuma, K., Sumiyoshi, Y., Kataoka, M. (2005). Long-term Outcomes of 60 Gy Conventional Radiotherapy Combined with Androgen Deprivation for Localized or Locally Advanced Prostate Cancer. Jpn J Clin Oncol 35: 655-659 [Abstract] [Full Text]  
• Raisz, L. G. (2005). Screening for Osteoporosis. NEJM 353: 164-171 [Full Text]  
• Sharifi, N., Gulley, J. L., Dahut, W. L. (2005). Androgen Deprivation Therapy for Prostate Cancer. JAMA 294: 238-244 [Abstract] [Full Text]  
• Lehman, R. (2005). Evidently.... Evid. Based Med. 10: 72-72 [Full Text]  
• (2005). Other articles noted. Evid. Based Med. 10: 95-96 [Full Text]  
• Seeman, E., Strewler, G. J. (2005). Clinical and Basic Research Papers - January 2005 Selections. IBMS BoneKEy 2: 1-6 [Full Text]  
• (2005). Endocrinology & Metabolism News February 2005. J. Clin. Endocrinol. Metab. 90: 16a-16a [Full Text]